Eco R1 Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History

Eco R1 Capital, LLC

$2.14 Billion
Q4 2024

A detailed history of Eco R1 Capital, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Eco R1 Capital, LLC holds 11,890,843 shares of APLS stock, worth $338 Million. This represents 17.73% of its overall portfolio holdings.

Number of Shares

11,890,843

Previous 11,890,843 -0.0%

Holding current value

$338 Million

Previous $343 Million 10.64%

% of portfolio

17.73%

Previous 14.88%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $8.17 Million - $11.7 Million	283,418 Added 2.44%	11,890,843 $343 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $9.52 Million - $14.9 Million	250,000 Added 2.2%	11,607,425 $445 Million
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $10.2 Million - $13.4 Million	184,357 Added 1.65%	11,357,425 $668 Million
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $10.1 Million - $17.7 Million	273,209 Added 2.51%	11,173,068 $669 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $129 Million - $486 Million	5,448,212 Added 99.94%	10,899,859 $415 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $12.5 Million - $18 Million	268,216 Added 5.17%	5,451,647 $360 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $40.8 Million - $62.2 Million	1,149,549 Added 28.5%	5,183,431 $263 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $124 Million - $198 Million	4,033,882 New	4,033,882 $191 Million
Q2 2018 Aug 14, 2018	SELL	$19.63 - $30.0 $20.7 Million - $31.7 Million	-1,056,348 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$14.01 - $26.02 $1.24 Million - $2.3 Million	-88,210 Reduced 7.71%	1,056,348 $23.4 Million
Q4 2017 Feb 14, 2018	BUY	$12.71 - $21.7 $14.5 Million - $24.8 Million	1,144,558	1,144,558 $24.8 Million

Others Institutions Holding APLS

# of Institutions

302

Shares Held

123M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.12B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.

Account

Eco R1 Capital, LLC Apellis Pharmaceuticals, Inc. Transaction History